GI
RAPP

GAMMA Investing’s Rapport Therapeutics RAPP Stock Holding History

GAMMA Investing’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Buy
408
+30
+8% +$1.1K ﹤0.01% 2934
2026
Q1 		$11.8K Buy
378
+36
+11% +$1.01K ﹤0.01% 2984
2025
Q4 		$10.4K Sell
342
-12
-3% -$332 ﹤0.01% 2962
2025
Q3 		$10.5K Sell
354
-91
-20% -$1.62K ﹤0.01% 2861
2025
Q2 		$5.06K Sell
445
-473
-52% -$5.02K ﹤0.01% 3109
2025
Q1 		$9.21K Buy
918
+908
+9,080% +$11.8K ﹤0.01% 2784
2024
Q4 		$177 Buy
+10
New +$222 ﹤0.01% 3717

Other funds holding RAPP

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing's RAPP Position: Q2 2026 in Review

GAMMA Investing increased its Rapport Therapeutics (RAPP) stake by 7.9% in Q2 2026, buying an estimated $1.1K and bringing the position to 408 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

GAMMA Investing first reported a position in RAPP in Q4 2024 and has held it in 7 quarters since. 8 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • GAMMA Investing held 408 shares of Rapport Therapeutics worth $17K as of Q2 2026.
  • GAMMA Investing bought 30 Rapport Therapeutics shares in Q2 2026, an estimated $1.1K.
  • Rapport Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2934 holding.
  • GAMMA Investing first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 8 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.